作者
Veronika Bachanova, David I Marks, Mei-Jie Zhang, Hailin Wang, Marcos de Lima, Mahmoud D Aljurf, Martha Arellano, Andrew S Artz, Ulrike Bacher, Jean-Yves Cahn, Yi-Bin Chen, Edward A Copelan, William R Drobyski, Robert Peter Gale, John P Greer, Vikas Gupta, Gregory A Hale, Partow Kebriaei, Hillard M Lazarus, Ian D Lewis, Victor A Lewis, Jane L Liesveld, Mark R Litzow, Alison W Loren, Alan M Miller, Maxim Norkin, Betul Oran, Joseph Pidala, Jacob M Rowe, Bipin N Savani, Wael Saber, Ravi Vij, Edmund K Waller, Peter H Wiernik, Daniel J Weisdorf
发表日期
2014/3/1
期刊
Leukemia
卷号
28
期号
3
页码范围
658-665
出版商
Nature Publishing Group
简介
The efficacy of reduced intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (HCT) for Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) is uncertain. We analyzed 197 adults with Ph+ ALL in first complete remission; 67 patients receiving RIC were matched with 130 receiving myeloablative conditioning (MAC) for age, donor type and HCT year. Over 75% received pre-HCT tyrosine kinase inhibitors (TKIs), mostly imatinib; 39%(RIC) and 49%(MAC) were minimal residual disease (MRD) neg pre-HCT. At a median 4.5 years follow-up, 1-year transplant-related mortality (TRM) was lower in RIC (13%) than MAC (36%; P= 0.001) while the 3-year relapse rate was 49% in RIC and 28% in MAC (P= 0.058). Overall survival (OS) was similar (RIC 39%(95% confidence interval (CI) 27–52) vs 35%(95% CI 27–44); P= 0.62). Patients MRD pos pre-HCT had higher risk of relapse …
学术搜索中的文章
V Bachanova, DI Marks, MJ Zhang, H Wang, M de Lima… - Leukemia, 2014
V Bachanova, D Marks, MJ Zhang, H Wang… - Biology of Blood and Marrow Transplantation, 2013